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Abstract. 15B3 is a monoclonal IgM antibody that selectively detects pathological aggregates of the prion protein (PrP).
We report the unexpected finding that 15B3 also recognizes oligomeric but not monomeric forms of amyloid- (A)42, an
aggregating peptide implicated in the pathogenesis of Alzheimer’s disease (AD). The 15B3 antibody: i) inhibits the bind-
ing of synthetic A42 oligomers to recombinant PrP and neuronal membranes; ii) prevents oligomer-induced membrane
depolarization; iii) antagonizes the inhibitory effects of oligomers on the physiological pharyngeal contractions of the nema-
tode Caenorhabditis elegans; and iv) counteracts the memory deficits induced by intracerebroventricular injection of A42
oligomers in mice. Thus this antibody binds to pathologically relevant forms of A, and offers a potential research, diagnostic,
and therapeutic tool for AD.
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INTRODUCTION21
The aberrant aggregation of amyloid- (A), even-22
tually leading to deposition of amyloid plaques in23
the brain, is a major hallmark of Alzheimer’s disease24
(AD). The main components of A plaques are A4025
and A42 peptides, in the form of ordered structures26
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with fibrillar morphology and high -sheet content. 27
Aggregation, ultimately leading to insoluble A fib- 28
rils, involves the formation of different intermediate 29
structures, including soluble oligomers and protofib- 30
rils, which are thought to play key pathogenic roles in 31
AD. Oligomers, in particular, disrupt brain synaptic 32
plasticity at relatively low concentrations [1–5]. 33
One of the main challenges in AD research is 34
the development of tools to distinguish different 35
aggregated forms of A [6]. We recently devel- 36
oped a surface plasmon resonance (SPR)-based 37
immunoassay that detects transient oligomeric 38
species generated during the incubation of synthetic 39
A42 [7]. This assay is based on the ability of the 40
anti-A antibody 4G8, immobilized on the sensor 41
chip, to bind oligomers in a pseudo-irreversible 42
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manner (i.e., with very slow dissociation), while43
monomers dissociate much faster. Using this assay,44
we serendipitously found that 15B3, a monoclonal45
antibody that recognizes misfolded/aggregated46
forms of the prion protein (PrP) implicated in prion47
diseases, could also bind oligomeric A42.48
15B3 is a mouse monoclonal IgM antibody49
obtained by immunizing PrP-null mice with full-50
length recombinant bovine PrP. The antibody was51
found to selectively recognize PrPSc, the infectious52
(prion) isoform of PrP [8], as well as non-infectious53
pathological aggregates of PrP [9–12]. Because of54
these properties, 15B3 is currently used to boost the55
sensitivity of a real-time quaking-induced conversion56
(RT-QuIC) assay for the detection of prions in biolog-57
ical samples [13]. Given the role of A oligomers in58
AD pathogenesis and the need for reagents that target59
these species for research, diagnostic, and therapeutic60
purposes, we thoroughly investigated the A binding61
properties of 15B3, and its ability to interfere with the62
toxic effects of A42 oligomers in animal models.63
MATERIALS AND METHODS64
Materials65
15B3 was obtained from Prionics (now Thermo66
Fisher Scientific, Rockford, IL USA). Three batches67
of 15B3 were used: most of the studies were carried68
out with batch # 071114A, with a nominal concentra-69
tion of 5 mg/mL; when indicated, batches # 11053170
(0.9 mg/mL) and # 061013 (0.8 mg/mL) were also71
used.72
Control mouse IgM was from Thermo Fisher Sci-73
entific, Rockford, IL, USA; anti-A monoclonal74
antibody 4G8 was from Covance, Princeton, NJ,75
USA; anti-A oligomer polyclonal antibodies OC76
and A11 were from Merck Millipore, Darmstadt, Ger-77
many; mouse monoclonal anti-A 6E10 was from78
Covance, Emerville, CA, USA; rabbit anti--tubulin79
was from Sigma, St. Louis, MO, USA and guinea pig80
anti-Bassoon was from Synaptic System, Gottingen,81
Germany.82
Aβ42 preparation83
Depsi-A42 was synthesized in-house, as previ-84
ously described [14]. In comparison with the highly85
aggregating A42, the more soluble depsi form has a86
much lower propensity for spontaneous aggregation87
[14, 15] preventing the formation of seeds in solution.88
A42 was then obtained from the depsi-peptide by a89
“switching” procedure involving a change in pH [16]. 90
The solution was diluted in 10 mM PBS, pH 7.4, to a 91
final concentration of 100M. This procedure allows 92
the preparation of reproducible, seed-free solutions 93
of monomeric A42, as shown by circular dichroism, 94
size exclusion chromatography, and SPR [7, 14]. To 95
obtain aggregated A42, the solution was incubated at 96
25◦C in quiescent conditions for different times. We 97
used freshly prepared solutions (t = 0) to have A42 98
monomers only, or A42 solutions incubated for 5 h 99
(t = 5 h) for maximal oligomer enrichment [7]. 100
SPR studies 101
The SPR apparatus we employed (ProteOn XPR36 102
Protein Interaction Array System; Bio-Rad) has six 103
parallel flow-channels that can be used to uniformly 104
immobilize six different ligands on the sensor sur- 105
face. The fluidic system can automatically rotate 90◦ 106
so up to six different analytes can be injected, allow- 107
ing simultaneous monitoring of up to 36 individual 108
molecular interactions in a single run on a single chip 109
[17]. 15B3 was immobilized in a flow channel of GLC 110
sensor chips (Bio-Rad) using amine coupling chem- 111
istry, as described [7]. Briefly, after surface activation, 112
the antibody (30g/mL in 10 mM acetate buffer, pH 113
5.0) was injected for 5 min at a flow rate of 30L/min, 114
and the remaining activated groups were blocked 115
with ethanolamine, pH 8.0. The final immobilization 116
level was about 7000 resonance units (1 RU = 1 pg of 117
protein/mm2). A “reference” surface was prepared 118
in parallel using the same immobilization procedure 119
without adding the antibody. Recombinant mouse 120
PrP, prepared as previously described [18, 19], was 121
also immobilized by amine coupling chemistry, as 122
previously described [20] (immobilization 3000 RU). 123
After rotation of the microfluidic system, A42 was 124
injected for 2 min at a flow rate of 30L/min. Disso- 125
ciation was measured in the next 11 min. The running 126
buffer, also used to dilute the samples, was 10 mM 127
PBS containing 0.005% Tween 20 (PBST). Assays 128
were run at 25◦C. The sensorgrams (time course of 129
the SPR signal in RU) were normalized to a base- 130
line of 0. The signal in the surfaces immobilizing the 131
antibody was corrected by subtracting the nonspecific 132
response observed in the reference surface. 133
Enzyme-linked immunosorbent assay (ELISA) 134
Synthetic A42 was dissolved in PBS to a final 135
concentration of 100M and incubated at 25◦C in 136
quiescent conditions. Aliquots were taken at different 137
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incubation times (from 0 to 72 h), diluted to 1M in138
PBS, loaded in triplicate on a 15B3-precoated 96-well139
microplate (Prionics, now Thermo Fisher Scientific,140
Rockford, IL, USA) and incubated 1 h at room tem-141
perature under shaking. The plate was washed four142
times with PBS containing 0.005% Tween-20 (PBST)143
and A42 oligomers were detected with HRP-labeled144
4G8 (Covance), 1 : 50 000 in PBST, incubated for 1 h145
at room temperature, protected from light. After four146
washes with PBST, Luminata Forte Western HRP147
Substrate (Millipore) was added and luminescence148
was measured with a F500 Infinite plate reader (Tecan149
Italia Srl, Italy).150
Kinetics of ﬁbril formation151
The kinetics of A42 aggregation was monitored152
using an in situ Thioflavin-T (ThT) fluorescence153
assay based on the increase of the fluorescence sig-154
nal of ThT when bound to -sheet-rich structures.155
A42, 4M, was incubated, with and without 15B3156
or control IgM, under quiescent conditions at 37◦C in157
microplate wells (Microplate Corning 3881, 96-well,158
low-binding, Corning Incorporated Life Sciences,159
Acton, MA) in the presence of 20M ThT (100L160
solution per well). ThT fluorescence was measured161
every 2.5 min using an F500 Infinity plate reader162
(Tecan Italia Srl, Italy). The dye was excited at163
448 nm (bandwidth 7 nm) and the emission measured164
at 485 nm (bandwidth 20 nm).165
Aβ42 binding to neurons166
Primary hippocampal neurons were established167
from Sprague Dawley E18 fetal rats (Charles168
River Italia). The experimental procedures followed169
the guidelines established by European (Direc-170
tive 2010/63/EU) and Italian legislation (L.D. no.171
26/2014). They were reviewed and approved by172
the Animal Welfare Committee of the University173
of Milan and by the Italian Ministry of Health.174
Briefly, dissociated cells were plated onto poly-L-175
lysine-treated coverslips at 520 cells/mm2 density176
and maintained in Neurobasal medium with 2% B27177
supplement and 2 mM glutamine (neuronal medium).178
12–15 DIV hippocampal neurons were exposed to179
1M A42 monomers or A42 oligomers for 1 h in180
neuronal medium. In one set of experiments, A42181
oligomers were preincubated with 10 nM 15B3 or182
control IgM for 30 min before being administered183
to neurons. Neurons were then washed, fixed with184
4% paraformaldehyde, and immunostained using the185
following antibodies: mouse monoclonal anti-A 186
6E10, rabbit anti--tubulin and guinea pig anti- 187
Bassoon. A binding to neurons was quantified using 188
the Image J 1.46r software by a modification of the 189
method previously described [21]. Briefly, A42 and 190
-tubulin double-positive puncta were revealed by 191
generating an A42/-tubulin double-positive image, 192
using the ‘and’ option of ‘image calculator’. A fixed 193
threshold was set in the double-positive image, and 194
the total co-localizing area was quantified using the 195
‘analyze particle’ function and normalized to total 196
-tubulin area in each field. 197
Electrophysiology 198
5000 HEK293T cells were seeded on 35-mm Petri 199
dishes and cultured for two days in DMEM with 200
4.5 g/L glucose, without L-glutamine (VWR Inter- 201
national PBI S.r.l., Milan, Italy), 10% fetal bovine 202
serum, 1% penicillin-streptomycin 100X (Life Tech- 203
nologies, Milan, Italy), 1% UltraGlutamine1 (Lonza 204
Group Ltd, Basel, Switzerland). HEK293T cells 205
were perfused with solutions containing 10M A42 206
monomers, A42 oligomers or A42 oligomers pre- 207
incubated for 30 min with 10 nM 15B3. Control cells 208
were treated with the vehicle. 209
Membrane potential was monitored in single 210
cells using the patch-clamp technique in configura- 211
tion perforated-patch, current-clamp mode. In brief, 212
patch-clamp pipettes (Garner Glass 7052) were made 213
using a P97 Sutter Instruments puller (Novato, CA) 214
and fire-polished to a tip diameter of 1–1.5m and 215
5–7 M resistance. The Axopatch 200 B amplifier 216
and pClamp 9 acquisition software and Clampfit 9 217
(both from Molecular Device, Novato, CA) were used 218
to record and analyze cell membrane voltages. Exper- 219
imental traces were digitized at 5 kHz and filtered at 220
1000 Hz. The bath solution contained (in mM) 136.5 221
NaCl, 5.4 KCl, 1.8 CaCl2, 0.5 MgCl2, 5.5 glucose, 5.5 222
HEPES, pH 7.4. The perforated-patch clamp config- 223
uration was achieved by adding to the pipette solution 224
(in mM) 135 KCl, 10 NaCl, 1 MgCl2, 10 HEPES pH 225
7.2, and the antibiotic gramicidin (Sigma Aldrich) 226
diluted to a final concentration of 7.5g/mL. This 227
solution was used to fill the patch pipette allowing 228
the pores in the membrane to open, to obtain electri- 229
cal access to the cell after about 5–10 min. With this 230
technique we can monitor the cell membrane poten- 231
tial for more than 30 min since cytoplasm dialysis is 232
hampered by the sieve formed by the antibiotic aper- 233
tures through the membrane which is permeable only 234
to monovalent cations. 235
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C. elegans experiments236
Bristol N2 strain, from the Caenorhabditis elegans237
Genetic Center (CGC; University of Minnesota),238
was propagated at 20◦C on solid nematode growth239
medium (NGM) seeded with OP50 Escherichia coli240
(from CGC) for food. To prepare age-synchronized241
animals, nematodes were transferred to fresh NGM242
plates on reaching maturity at three days of age and243
allowed to lay eggs overnight. Isolated hatchlings244
from the synchronized eggs (day 1) were cultured on245
fresh NGM plates at 20◦C. For pumping-rate assays,246
nematodes (L3-L4 larval stage) were collected with247
M9 buffer, centrifuged, and washed twice with 5 mM248
PBS, pH 7.4 to eliminate bacteria. The worms were249
incubated with A42 without E. coli to avoid inter-250
ference and bacteria-mediated peptide degradation.251
Worms (100 worms/100L) were incubated with252
10M oligomeric A42 in 10 mM PBS (pH 7.4)253
alone or with the 15B3 antibody or control IgM. After254
2 h, worms were transferred onto NGM plates seeded255
with OP50 E. coli. The pharyngeal pumping rate was256
scored 2 h later by counting the number of times the257
terminal bulb of the pharynx contracted in a 1-min258
interval (pumps/min).259
Mouse studies260
C57BL/6 mice were obtained from Charles River261
Laboratories (Calco, Italy). Procedures involving ani-262
mals and their care were conducted in conformity263
with the institutional guidelines at the IRCCS –264
Mario Negri Institute for Pharmacological Research265
in compliance with national (Decreto Legislativo 4266
marzo 2014, n.26) and international laws and policies267
(EEC Council Directive 2010/63/UE; Guide for the268
Care and Use of Laboratory Animals, U.S. National269
Research Council (Eighth Edition) 2011). They were270
reviewed and approved by the Mario Negri Institute271
Animal Care and Use Committee which includes ad272
hoc members for ethical issues, and by the Italian273
Ministry of Health. Animal facilities meet inter-274
national standards and are regularly checked by a275
certified veterinarian who is responsible for health276
monitoring, animal welfare supervision, experimen-277
tal protocols, and review of procedures.278
Intracerebroventricular (i.c.v.) cannulation was279
done as described [5]. Briefly, 10-week-old mice280
were anesthetized with Forane (Abbott Laboratories)281
and mounted on a stereotaxic apparatus (model 900,282
David Kopf Instruments, Tujunga, CA). A 7-mm-283
long guide cannula was implanted into the cerebral284
lateral ventricle (lateral±1.0 and dorsal-ventral –3.0 285
from the dura with an incisor bar at 0◦) and secured 286
to the skull with two stainless steel screws and dental 287
cement. Mice were allowed 10–15 days to recover 288
from surgery before the experiment. 289
A42 oligomers were prepared as described above, 290
and diluted to a final concentration of 1M before 291
i.c.v. microinfusion (7.5L/mouse). To test the effect 292
of 15B3, mice were treated 5 min before the injection 293
of A42 oligomers with 0.25g of antibody in 2L 294
of PBS. The novel object recognition test (NORT) 295
was run as described [5]. Briefly, mice are trained 296
in an arena containing two objects that they can 297
explore freely (familiarization phase). Twenty-four 298
hours later, the mice are exposed to one familiar and 299
one new object (test phase). Memory was expressed 300
as a discrimination index, i.e., the time spent explor- 301
ing the novel object minus the time spent exploring 302
the familiar object, divided by the total time spent 303
exploring both objects; the higher the discrimination 304
index, the better the performance. 305
RESULTS 306
15B3 recognizes oligomeric but not monomeric 307
forms of synthetic Aβ42 308
A42 was dissolved in PBS to a final concentration 309
of 100M and incubated at 25◦C in quiescent con- 310
ditions. Aliquots were then taken at different times 311
(from 0 to 72 h), diluted to 1M in PBS and flowed 312
over SPR sensor chips on which the 15B3 antibody 313
had been immobilized. Figure 1A shows that the 314
binding signal on 15B3 was markedly affected by 315
the length of incubation of A42. No binding sig- 316
nal was observed on injecting the freshly prepared 317
solution (t = 0), whereas a marked increase was seen 318
with solutions analyzed after 1, 2, and 5 h; with 319
longer incubation (8, 24, and 72 h), the signal progres- 320
sively declined (Fig. 1A,B). Injection of the 5-h A42 321
solution over immobilized control IgM resulted in a 322
binding signal about 80% lower than that on immo- 323
bilized 15B3 (Fig. 1C), supporting the specificity of 324
the interaction. Results were confirmed by sandwich 325
ELISA: 96-well microplates pre-coated with 15B3 326
were incubated with aliquots of A42 solution taken 327
at 0–72 h. After washing, 15B3-captured A42 was 328
detected using HRP-conjugated 4G8 antibody and 329
chemiluminescence. The time-course of binding was 330
similar to that obtained by SPR, with the highest 331
signal at 5 h (Fig 1D). 332
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A B
C D
Fig. 1. Surface plasmon resonance (SPR) and ELISA studies. Synthetic A42 (100M) was incubated at 25◦C, and samples were taken at
different times (from 0 to 72 h), diluted to 1M in 10 mM PBS, pH 7.4, and flowed (SPR) or incubated (ELISA) on immobilized 15B3. A)
Sensorgrams (time course of the SPR signal expressed in resonance units, RU) obtained from a representative experiment in which A42
solutions were flowed for 2 min (bar), followed by 11 min of dissociation. B) Effect of the length of incubation of A42 on its binding to
15B3 immobilized on the SPR sensor chip. Each value is the mean ± SD of three different experiments. C) Sensorgrams obtained flowing
the 5-h A42 solution over parallel sensor surfaces on which 15B3 or control IgM had been previously immobilized (immobilization levels
respectively 7040 and 7050 RU); this experiment was replicated twice with identical results. D) Effect of the length of incubation of A42
on its binding to 15B3 immobilized on ELISA plates. Mean ± SD of three replicates.
We previously demonstrated [7] that freshly pre-333
pared A42 solution (t = 0) contained only monomers,334
whereas the solution incubated for 5 h contained a335
heterogeneous population of SDS-labile aggregates,336
including globular species and short protofibrils,337
with a main hydrodynamic diameter of 10–30 nm.338
The solution incubated for 24 h mainly contained339
larger, SDS-stable species [7]. Thus, 15B3 selectively340
recognized a specific population of soluble A42341
oligomers, but not A42 monomers or higher-order342
aggregates343
The pseudo-irreversible binding observed around344
t = 5 h suggests multivalent interactions between dif-345
ferent epitopes on a single oligomeric assembly and346
several immobilized 15B3 molecules. The affinity347
of the oligomers for 15B3 could not be determined348
because of the lack of information about their actual349
concentration, due to uncertainties about their precise350
molecular mass. However, based on previous analy- 351
sis by size exclusion chromatography we can assume 352
that after 5 h of incubation 40% of the monomers 353
have assembled into oligomers with a mass range 354
from 90 to 400 kDa [7, 22]; it follows that the con- 355
centration of oligomers is in the low nanomolar range 356
(4–20 nM) and their affinity for 15B3 is exceptionally 357
high (KD < 1 nM). 358
The oligomeric population selectively recognized 359
by 15B3 was also recognized by the anti-A antibody 360
4G8, and by OC, a conformation-specific antibody 361
believed to selectively target fibrillar oligomers [23], 362
as shown by an SPR assay in which 4G8 or OC 363
were flowed onto 15B3-captured oligomers (Fig. 2). 364
This oligomeric population was not recognized by the 365
other widely-used anti-oligomer antibody A11, nei- 366
ther in this SPR format (Fig. 2), nor when the A42 367
solution was flowed onto A11 immobilized on the 368
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A
B
Fig. 2. SPR studies showing binding of 4G8 and OC, but not A11,
to 15B3-captured A42 oligomers— Synthetic A42 (100M)
was incubated at 25◦C, sampled after 5 h, diluted to 1M in
10 mM PBS, pH 7.4, and injected over immobilized 15B3 (batch
# 071114A) for 5 min, followed by injection of two different con-
centrations of 4G8 (A), OC or A11 (B) antibodies for 2 min (bars).
The binding of 4G8 to captured oligomers (A) confirms the data
shown in Fig. 1D. The experiment shown in B was replicated three
times with very similar results.
sensor chip (data not shown). Dot-blot analysis con-369
firmed the presence of species recognized by OC but370
not A11 in the 5-h A42 solution (data not shown).371
15B3 inhibits Aβ42 ﬁbrillogenesis372
Next we tested whether 15B3 binding to the soluble373
A42 assemblies formed early in the aggregation pro-374
cess affected subsequent fibril formation. A freshly375
prepared 4-M solution of A42 was incubated with376
20M thioflavinT (ThT) with or without 15B3 or377
control IgM, and the ThT fluorescence was monitored378
for 24 h [14]. A42 fibrillogenesis had a lag phase of379
2 h, followed by very rapid growth, reaching a plateau380
after 5 h (Fig. 3A). Control IgM, up to 40 nM, did not381
significantly affect this process, whereas 15B3 shifted382
the curves in a dose-dependent manner, increasing383
the half-time of transition (Fig 3B). There was some384
batch-to batch variability in the effects of 15B3, with385
A
B
C
Fig. 3. Effect of 15B3 on A42 fibrillogenesis, evaluated by ThT
fluorescence—Synthetic A42 (4M) was incubated with ThT
(20M) with or without 15B3 or control IgM, and ThT fluores-
cence was monitored every 2.5 min. Three batches of 15B3 were
used for these studies, as indicated. A) Representative raw fluores-
cent values. B) Normalization of the data in A on the corresponding
maximal values to illustrate better the shift in the half-time of
transition, i.e., the time corresponding to half the maximum ThT
signal. C) Half-time of transition of A42 in the presence of differ-
ent concentrations of the antibodies. Antibodies are identified by
the colors; open or solid symbols indicate results of independent
experiments.
batch 071114A about four times more potent than 386
batches 061013 and 110531 (Fig. 3B). This might 387
reflect subtle structural differences between anti- 388
bodies of different batches, perhaps due to variable 389
expression conditions, which might affect glycosyla- 390
tion and/or the intrinsic tendency of IgM to aggregate. 391
These data suggest that 15B3 binds to oligomeric 392
intermediates on the pathway of A42 fibrillation. A 393
similar effect on A42 fibrillogenesis was observed 394
with N1, a physiological N-terminal cleavage 395
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Fig. 4. Effect of 15B3 on the binding of A42 oligomers to
recombinant mouse PrP (rmPrP) immobilized on the sensor
chip—Synthetic A42 (100M) was incubated at 25◦C, sampled
after 5 h, diluted to 1M in 10 mM PBS, pH 7.4, and incubated
for another 30 min with or without 15B3 (4.2 and 8.4 nM, lot
# 061013). Aliquots were then injected for 3 min (bar) over immo-
bilized rmPrP. The figure shows the sensorgrams (time course of
the SPR signal expressed in resonance units, RU) from a repre-
sentative experiment. This study was replicated twice with very
similar results.
fragment of PrP, which also selectively interacts with396
A42 oligomers [24].397
15B3 inhibits the binding of Aβ42 oligomers to398
recombinant PrP and to rat hippocampal399
neurons, and prevents oligomer-induced400
membrane depolarization401
As a first step to assess the biological impor-402
tance of the 15B3-A42 interaction, we investigated403
the antibody’s ability to counteract the binding of404
A42 oligomers to recombinant mouse PrP (rmPrP),405
since cellular PrP (PrPC) may mediate oligomer-406
induced neurotoxic signaling [25]. A42 oligomers407
bound rmPrP immobilized on the sensor chip with408
high affinity, confirming previous results [5, 20]409
(Fig. 4). Preincubation of oligomers with 15B3 for410
30 min resulted in dose-dependent reduction of bind-411
ing (Fig. 4). 15B3 did not bind to immobilized rmPrP412
(data not shown).413
Next, we analyzed the antibody’s ability to414
counteract the binding of A42 oligomers to rat415
hippocampal neurons [21]. Incubating neurons with416
monomeric A42 did not result in A binding to417
the neuronal surface, as shown by the lack of stain-418
ing with the anti-A antibody 6E10 (Fig. 5A). In419
contrast, a strong immunopositive signal was seen420
on the surface of neurons incubated with the A421
oligomer-containing solution (Fig. 5B). Preincuba-422
tion of oligomers with 15B3 significantly reduced423
binding. This was clearly seen with batch 071114A424
(Fig. 5E); less so with batch 061013 (Fig. 5F), con- 425
sistent with their different ability to inhibit A42 426
fibrillogenesis (Fig. 3). Control IgM (10 nM) had 427
no effect on binding (Fig. 5F), and there was no 428
6E10-positive signal when neurons were incubated 429
with 15B3 alone (data not shown). Experiments in 430
which 15B3 was used to immunostain neurons that 431
had been previously incubated with synthetic A42 432
oligomers were unrewarding. In fact, 15B3 could not 433
even immunodetect pathological PrP in brain sec- 434
tions from prion diseased patients and mice ([10] and 435
unpublished results), indicating that this antibody is 436
not suitable for immunostaining. 437
Finally, we tested whether 15B3 protected cells 438
from the effects of A42 oligomers on cell mem- 439
brane potential. We used HEK293T cells, monitoring 440
the cell membrane resting potential by a perforated- 441
patch current-clamp technique [26]. HEK293T cells 442
have a reduced set and a lower number of ion chan- 443
nels, and compensate small changes in membrane 444
potential less efficiently than primary neurons, and 445
are therefore more sensitive to the effects of A42. 446
Acute exposure of cells to A42 oligomers, but not 447
monomers, resulted in significant membrane depo- 448
larization, and this effect was completely abolished 449
by 15B3 (Fig. 6). 450
15B3 prevents the toxic effects of Aβ42 oligomers 451
on C. elegans pharynx 452
We investigated the ability of 15B3 to counter- 453
act A oligomer toxicity in vivo. First we used the 454
invertebrate nematode C. elegans, whose pharyngeal 455
behavior is sensitive to sublethal doses of chemical 456
stressors. We previously reported that both rhythmic 457
contraction and relaxation of the pharyngeal muscle 458
in C. elegans, scored as “pumping rate”, were signif- 459
icantly impaired by feeding the nematodes synthetic 460
A42 oligomers, but not monomers or fibrils [7]. Here 461
we tested whether pre-incubation of 15B3 with A42 462
oligomers prevented this effect (Fig. 7). Consistent 463
with previous observations, A42 oligomers signifi- 464
cantly reduced the worm pumping rate, and this effect 465
was dose-dependently antagonized by 15B3 but not 466
by control IgM. 15B3 alone had no effect on the 467
pumping rate (Fig. 7). 468
15B3 prevents the memory deﬁcits induced by 469
Aβ42 oligomers in mice 470
We previously reported that synthetic A42 471
oligomers injected i.c.v. in C57BL/6 mice caused 472
memory impairment in the novel-object recognition 473
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E F
Fig. 5. Effect of 15B3 on the binding of A42 oligomers to rat hippocampal neurons— A–D) Representative images obtained exposing
12–15 DIV hippocampal neurons for 1 h to solutions containing (A) A42 monomers or (B) A42 oligomers. The final concentration of
A42 was 1M in both cases. C, D) Neurons exposed to 1M A42 monomers or oligomers pre-incubated for 30 min with 15B3 (batch #
071114A, 10 nM). Neurons were washed, fixed with 4% paraformaldehyde and stained using the following antibodies: mouse anti-A, 6E10
(green), rabbit anti- tubulin (red) and guinea pig anti-Bassoon (blue). E) Corresponding quantification of 6E10 binding to cultured neurons
expressed as colocalizing area between 6E10 and -tubulin, relative to total -tubulin. Mean ± SEM of 20 fields from two independent
experiments, ∗p < 0.05 Dunn’s test after Kruskal-Wallis One Way Analysis of Variance on Ranks (this statistical analysis was used because
the normality test failed). F) Quantification of a third experiment with 15B3 batch # 061013 and control IgM, both 10 nM. Mean ± SEM of
10 fields, ∗p < 0.05 Holm-Sidak test after One Way Analysis of Variance (used because the normality test passed).
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Fig. 6. Effect of 15B3 on membrane potential depolarization
caused by A42 oligomers—HEK293T cells were perfused
with solutions containing 10M A42 monomers, 10M A42
oligomers, or 10M A42 oligomers pre-incubated for 30 min
with 10 nM 15B3, batch # 071114A. Control cells were treated
with the vehicle. Data are expressed as median and interquartile
range, as well as single values (12, 16, 14, and 11 cells for the four
groups). ∗p < 0.05; one-way ANOVA, Tukey’s post hoc test.
task [5]. This was not seen using either Amonomers474
or fibrils, indicating that A oligomers are the molec-475
ular species responsible for the amnesic effect [24].476
We used this acute in vivo mouse model to eval-477
uate whether 15B3 prevented the deleterious effects478
of A42 oligomers on memory. As expected, mice479
receiving 1M A42 oligomers, i.c.v., had a signifi-480
cantly lower discrimination index compared to mice481
injected with the vehicle solution (Fig. 8). No effect482
of A42 oligomers was seen in mice pre-treated i.c.v.483
with 15B3 (0.25g/2L, 5 min before oligomers)484
(Fig. 8).485
DISCUSSION486
In the present study we show that 15B3, an487
anti-prion antibody known for its ability to specif-488
ically recognize PrPSc and other pathogenic PrP489
aggregates [8–11], also recognizes aggregated, but490
not monomeric, A42. In particular, our data show491
that 15B3 interacts with a transient population of492
oligomers of synthetic A42 that have substantial493
biological and pathogenic effects.494
The soluble oligomers recognized by 15B3 form495
progressively during incubation of synthetic A42,496
reaching a peak concentration after 5 h, then dis-497
appearing. Previous analysis showed that the 5-h498
solution contains a heterogeneous population of499
SDS-labile structures, including globular oligomers500
and short protofibrils, with a main hydrodynamic501
A
B
Fig. 7. Effect of 15B3 on the ability of A42 oligomers to reduce
the pharyngeal motility of C. elegans—Synthetic A42 (100M)
was incubated at 25◦C for 5 h, diluted to 10M and incubated
with 10 nM or 50 nM 15B3 antibody or 50 nM control IgM, or the
vehicle (PBS). The solutions were incubated for another 30 min
before being given to the worms. Nematodes were fed for 2 h
with these solutions, then plated on Nematode Growth Medium
plates seeded with OP50 E. coli. The pharyngeal pumping rate was
scored 2 h after plating. Data are expressed as minimum to maxi-
mum box and whisker plots (10–20 worms/group from one or two
independent experiments). Panels A and B show the results with
15B3 batches # 071114A and # 110531, respectively. ∗∗p < 0.01
effect of A42 oligomers versus corresponding vehicle; ◦p < 0.05,
◦◦p < 0.01 effect of 15B3 versus corresponding vehicle, Bonfer-
roni’s test after two-way ANOVA.
diameter of 10–30 nm [7]. These species have impor- 502
tant biophysical and biological properties: i) they bind 503
recombinant PrP and may therefore be responsible for 504
the previously described PrPC-mediated neurotoxic 505
effects [5, 20, 24, 25, 27–32]; ii) they bind to neurons 506
and raise the cell membrane potential, a mechanism 507
that may contribute to their toxicity [33, 34]; iii) they 508
slow the pumping rate of the C. elegans pharynx 509
[7, 35, 36]; and iv) they impair recognition memory 510
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Fig. 8. A42 oligomer-induced memory impairment in mice is
prevented by pretreatment with 15B3—Bars show the discrimina-
tion index, calculated as follows: (time on novel object – time on
familiar object)/(total time on objects). Data are expressed as the
mean ± standard error (SE) (n = 5–7). Two-way ANOVA showed
a significant interaction between A42 and 15B3 (p < 0.01).
∗∗p = 0.01 effect of A42 oligomers versus corresponding vehi-
cle; ◦◦p < 0.01 effect of 15B3 versus corresponding vehicle, post
hoc Bonferroni’s test. Batch # 071114A of 15B3 was used for these
experiments.
when injected i.c.v. in mice [5]. All these effects511
are prevented by mixing the 5-h A42 solution with512
nanomolar concentrations of 15B3. This is probably513
due to the antibody’s ability to directly bind a sub-514
population of bioactive A42 oligomers. 15B3 might515
promote oligomer disassembly. However, if this were516
the case the SPR signal indicative of their interac-517
tion should rapidly decrease, whereas we observed a518
very stable interaction (Fig. 1A). Alternatively, 15B3519
might shield certain patches on the surface of A520
oligomers, responsible for their interaction with PrPC521
and/or other components of cell membranes, and for522
their in vitro and in vivo toxicity. Structurally simi-523
lar patches are probably also exposed by toxic PrP524
assemblies which interact with 15B3 [8–10, 13].525
It was suggested that one of the main determinants526
of oligomer toxicity is surface hydrophobicity [37].527
Supporting this, it was found that A oligomers inter-528
act with and disrupt cellular membranes depending529
on the degree of solvent exposure of their central and530
C-terminal hydrophobic segments [38]. Our SPR data531
indicate that the 15B3-captured A42 oligomers are532
recognized by 4G8, a monoclonal antibody that binds533
to the central hydrophobic region of A, indicating534
that they expose hydrophobic toxic domains. How-535
ever, in sharp contrast to 4G8 [7], 15B3 does not bind536
monomeric A42.537
Different antibodies have been described which538
target different A oligomeric species [39], consis-539
tent with the highly heterogeneous nature of these 540
assemblies [40]. These include A11 and OC, poly- 541
clonal IgGs targeting “prefibrillar” and “fibrillar” 542
oligomers, respectively [41, 42]; NU-1, A-887755a 543
and 11A1, monoclonal IgGs targeting A-derived 544
diffusible ligands (ADDLs) [43], globulomers [44], 545
and “toxic A42 conformer” [45], respectively; and 546
the “oligomer-specific” IgM OMAB [46]. All these 547
antibodies were generated using an A antigen 548
whereas15B3 was raised against a heterologous pro- 549
tein (PrP). Other monoclonal antibodies have been 550
raised against PrP that can bind soluble oligomers 551
of both PrPSc and A [47]; however, the A-binding 552
properties of these antibodies were not characterized. 553
Our SPR data indicate that the oligomeric population 554
detected by 15B3 is also recognized by the OC, but 555
not the A11 antibody. OC is a conformational anti- 556
body raised by immunizing rabbits with A42 fibrils, 557
but detecting different types of amyloid, including 558
-synuclein, islet amyloid polypeptide and polyQ 559
fibrils, in addition to soluble oligomeric fragments 560
of A42 fibril protofilament [42, 48]. The fibrillar 561
oligomers recognized by OC are immunologically 562
distinct from the prefibrillar oligomers recognized by 563
A11, even though their sizes broadly overlap [48]. 564
Analysis in brain extracts from AD patients [49] and 565
transgenic mice [50] showed that an increase in OC- 566
positive oligomers correlated with cognitive decline 567
and neuropathological changes, whereas increased 568
levels of A11-positive oligomers did not. These data 569
therefore suggest that the A oligomers recognized 570
by 15B3 are pathologically relevant species that 571
expose the OC but not the A11 epitope. 572
The 15B3-based SPR immunoassay may represent 573
a convenient technique for checking the formation 574
of bioactive oligomers of synthetic A42, e.g., for 575
investigating the effect of mutations on the kinet- 576
ics of A oligomerization [51] or for characterizing 577
the mechanism of action of compounds that inhibit 578
A aggregation, such as EGCG and N1 [7, 24]. The 579
15B3 antibody is particularly suitable for SPR-based 580
immunoassay, since only highly purified antibodies 581
can be reliably immobilized on sensor chips, and 582
other commercially available anti-oligomer antibod- 583
ies, such as OC antiserum, lack this requisite. The 584
present study was carried out using synthetic prepa- 585
rations of A42 oligomers, and further studies are 586
underway to evaluate if 15B3 also recognizes A 587
oligomers in AD patients. 588
If this were the case, 15B3-based immunoassays 589
could be used for implementing diagnostic AD tests 590
based on detection of A oligomers in biological 591
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fluids, for example to boost the sensitivity of pro-592
tein misfolding cyclic amplification or QuIC assays593
of A [52]. 15B3 may also be used for immunop-594
urifying biologically active A species, as has been595
done for pathogenic forms of PrP [11]. Finally, the596
evidence that 15B3 neutralizes A42 oligomer toxic-597
ity in C. elegans and mice calls for further studies to598
assess its potential for the immunotherapy of AD.599
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